2021 annual financial data
BioCryst Pharmaceuticals 2021 Operating cash flow margin
Direct answer
Operating cash flow margin was -90.45%.
Operating income was -177,720,000 USD and net income was -184,062,000 USD.
Operating cash flow was -142,157,000 USD.
Get free BioCryst Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 157,170,000 USD
- Operating income
- -177,720,000 USD
- Net income
- -184,062,000 USD
- Operating cash flow
- -142,157,000 USD